DelveInsight sees Graves’ orbitopathy market poised for disruption as new drugs approach
The Graves’ orbitopathy treatment market was worth $2.1 billion in 2024 across leading regions, with the USA accounting for 96% of sales, according to a new DelveInsight report.
Amgen’s (Nasdaq: AMGN) Tepezza (teprotumumab-trbw) remains the only approved drug for now, generating $1.85 billion in revenue in 2024, underscoring its dominant position.
Tepezza’s patent protection gives Amgen a temporary moat, but looming launches threaten its near-monopoly. Analysts expect newcomers to carve out share by offering more convenient subcutaneous dosing or better tolerability. A positive scientific opinion this year has also opened the door for Tepezza in Europe, expanding the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze